Perceptive Advisors’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Perceptive Advisors’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Hold	0	–	–	–	159
2017 Q1	–	Sell	-500	Closed	-$448K	–	208
2016 Q4	$490K	Buy	+500	New	+$571K	0.03%	119
2015 Q3	–	Sell	-500	Closed	-$1.29M	–	190
2015 Q2	$1.29M	Hold	500	–	–	0.08%	112
2015 Q1	$1.4M	Buy	+500	New	+$1.31M	0.11%	90

Other funds holding TCON

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Perceptive Advisors's TCON Position: Q2 2017 in Review

Perceptive Advisors held its TRACON Pharmaceuticals, Inc. Common Stock (TCON) position steady in Q2 2017 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #159.

Perceptive Advisors first reported a position in TCON in Q1 2015 and has held it in 3 quarters since. The position peaked at $1.4M in Q1 2015. 26 funds tracked by Wall St. Rank hold TCON as of Q2 2017.

Perceptive Advisors held 0 shares of TRACON Pharmaceuticals, Inc. Common Stock worth $0 as of Q2 2017.
Perceptive Advisors left its TRACON Pharmaceuticals, Inc. Common Stock share count unchanged in Q2 2017.
TRACON Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Perceptive Advisors's portfolio in Q2 2017, its #159 holding.
Perceptive Advisors first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2015 and has held it in 3 quarters since.
Perceptive Advisors's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $1.4M in Q1 2015.
26 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.